Innovative Phar (00399.HK) announced that its subsidiary Fushi renewed its cooperation agreement with Beijing Tsinghua University for the development of oral insulin products, with the term renewed until June 30, 2027.

The company is conducting the third phase B clinical trial of the product, and the recruitment of the first batch of patients for the clinical trial began in July 2020. As of March 31, 2024, about 400 patients have been recruited in designated participating hospitals to participate in the clinical trial. The patient recruitment process will continue. According to the latest available information, the product's commercialization timetable has been revised, and it is expected that the product will be launched into the market in the first quarter of 2026 and sold in designated hospitals.

The company expects a stable source of income and profits to be generated after the launch of the product.